South African Pharmacist’s Assistant (SAPA) is the official mouthpiece of the Pharmaceutical Society of South Africa (PSSA). SAPA is aimed at pharmacist’s assistants (PAs) who have undergone formal basic and post-basic training and who are registered with the South African Pharmacy Council. PAs work under close supervision of the pharmacist and are trained to advise the public on all self-medication issues. They are allowed to dispense schedule 0-2 medicines or so-called over the counter preparations in South Africa. SAPA provides the PA with the necessary clinical as well as drug information in order to advise customers on the prudent use and limitations of self-medication. Clear guidelines are given as to when self-medication is appropriate and when medical attention may be necessary. The PA also assists the pharmacist in other pharmaceutical functions like stock taking, storing of medicines, preparing and mixing medicines and filling scripts under the pharmacist’s supervision. The content of the journal is seasonal to closely reflect what is happening in the pharmacy

Jardiance Declared Best International Pharmaceutical Product 2018

Jardiance Declared Best International Pharmaceutical Product 2018 Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best...

Maternal mortality – Fact Sheet

Maternal mortality - Fact SheetMSD for Mothers     Global statistics1 • Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth. • 99% of all maternal deaths occur in developing countries. • Maternal mortality is...

CIPLA LAUNCHES NEW TRIPLE-COMBINATION ANTIRETROVIRAL DRUG, REYDIN

Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla is launching its new triple-combination ARV treatment for HIV in South Africa.

Empagliflozin proven to improve clinical outcomes in real world practice across a broad spectrum of cardiovascular risk

The most recent 2018 treatment recommendations from the American Diabetes Association are that, after considering drug specific and patient factors, treatment for people with atherosclerotic cardiovascular disease (ASCVD) should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and/or cardiovascular mortality.

Skin protection range, Dexeryl, receives Allergy Foundation’s seal of approval

Partnership brings established international brand to South African consumers with complementary barrier and cleansing presentations for dry skins.

Wildcard SSL